Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAN T LA

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1437178274
CMS profile
19190
Location
TUJUNGA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$4,407.74

217 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $4,407.74 217

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 5; records 101–150 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAN T LA

NPI 1437178274 · CMS profile ID 19190

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

TUJUNGA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 5; records 101–150 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1437178274?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAN T LA, NPI 1437178274, CMS profile ID 19190. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437178274?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DAN T LA, NPI 1437178274, CMS profile ID 19190. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437178274?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DAN T LA, NPI 1437178274, CMS profile ID 19190, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 217 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1437178274?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

217 matching records · $4,407.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 217 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 217.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $34.9307/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825238561 CMS
UCB, Inc. $85.3307/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807418473 CMS
Janssen Biotech, Inc. $24.6807/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788233275 CMS
AbbVie Inc. $19.5207/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795189527 CMS
AbbVie Inc. $26.9107/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795189533 CMS
Novartis Pharmaceuticals Corporation $19.4407/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813088521 CMS
PFIZER INC. $20.0507/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832729878 CMS
Novartis Pharmaceuticals Corporation $9.1907/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813088517 CMS
E.R. Squibb & Sons, L.L.C. $11.4307/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783621767 CMS
Horizon Therapeutics plc $16.6807/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797162113 CMS
AbbVie Inc. $9.3306/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795189521 CMS
Janssen Biotech, Inc. $26.8806/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788233289 CMS
Amgen Inc. $11.2106/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825238657 CMS
Amgen Inc. $17.3906/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825238505 CMS
Horizon Therapeutics plc $24.8906/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797162111 CMS
Novartis Pharmaceuticals Corporation $17.0106/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813088513 CMS
Amgen Inc. $23.5806/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825238557 CMS
GlaxoSmithKline, LLC. $31.4806/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802983192 CMS
UCB, Inc. $6.2306/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807397575 CMS
E.R. Squibb & Sons, L.L.C. $0.3106/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783621759 CMS
E.R. Squibb & Sons, L.L.C. $24.9006/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783621761 CMS
UCB, Inc. $6.2006/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807399909 CMS
UCB, Inc. $25.3306/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807397573 CMS
Horizon Therapeutics plc $15.2406/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797162109 CMS
Horizon Therapeutics plc $19.3706/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797162107 CMS
AbbVie Inc. $8.1506/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795189515 CMS
Novartis Pharmaceuticals Corporation $18.5506/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813088509 CMS
Amgen Inc. $29.7606/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825238653 CMS
E.R. Squibb & Sons, L.L.C. $8.8706/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783621751 CMS
Amgen Inc. $23.3305/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825238553 CMS
Horizon Therapeutics plc $5.2505/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797162105 CMS
Horizon Therapeutics plc $16.1605/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797162103 CMS
AbbVie Inc. $22.7005/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795189509 CMS
Amgen Inc. $28.4705/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825238501 CMS
Amgen Inc. $12.2305/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825238645 CMS
AbbVie Inc. $18.6305/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795189505 CMS
AbbVie Inc. $3.8705/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795189499 CMS
Janssen Biotech, Inc. $22.9305/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788233287 CMS
Amgen Inc. $25.7505/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825238497 CMS
Amgen Inc. $2.7805/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825238545 CMS
AbbVie Inc. $29.7605/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795189493 CMS
Amgen Inc. $16.0205/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825238493 CMS
Amgen Inc. $30.2805/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825238549 CMS
Lilly USA, LLC $22.9505/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819046169 CMS
Horizon Therapeutics plc $27.5705/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797162101 CMS
Amgen Inc. $27.8605/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825238649 CMS
E.R. Squibb & Sons, L.L.C. $17.3705/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783621735 CMS
AbbVie Inc. $16.6704/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795189487 CMS
Janssen Biotech, Inc. $21.6804/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788233285 CMS
Amgen Inc. $27.9404/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825238541 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $18,400.54 339
PY2020 $6,563.18 236
PY2021 $4,407.74 217
PY2022 $5,342.69 240
PY2023 $4,424.46 194
PY2024 $5,959.53 210
PY2025 $5,095.82 180

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,365,187.27 27
PY2024 Recipient $109.58 2
PY2024 Principal investigator $862,088.22 28
PY2023 Recipient $158.40 1
PY2023 Principal investigator $363,453.96 72
PY2022 Recipient $56.00 1
PY2022 Principal investigator $424,809.05 58
PY2021 Principal investigator $528,113.90 37
PY2020 Recipient $45.90 1
PY2020 Principal investigator $438,287.25 14
PY2019 Principal investigator $48,433.90 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $5,939.10 11/05/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192185479
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,695.13 10/08/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190303259
Principal investigator 1 GlaxoSmithKline, LLC. $2,981.70 08/01/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192185490
Principal investigator 1 Amgen Inc. $575.11 07/28/2025 Non-covered Recipient Entity
MEDVIN CLINICAL RESEARCH - CACTUS AVENUE
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246644337
Principal investigator 1 Amgen Inc. $2,989.15 07/28/2025 Non-covered Recipient Entity
MEDVIN CLINICAL RESEARCH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity No dispute reported 06/30/2026 1246644346
Principal investigator 1 Eli Lilly and Company $4,392.00 07/23/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187875803
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,000.00 07/18/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223282844
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 07/18/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223282846
Principal investigator 1 American Regent $89,416.80 07/14/2025 Non-covered Recipient Entity
Biovin Enterprise LLC
TPX-100 No dispute reported 06/30/2026 1232689991
Principal investigator 1 Eli Lilly and Company $16,216.00 07/14/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187876179
Principal investigator 1 Eli Lilly and Company $104,834.00 06/17/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187875791
Principal investigator 1 GlaxoSmithKline, LLC. $6,915.60 06/04/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192185486
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $31,140.00 06/04/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH ACTIVE PRIMARY SJGRENS SYNDROME (PSS) No dispute reported 06/30/2026 1225335921
Principal investigator 1 GlaxoSmithKline, LLC. $5,908.50 05/09/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192156703
Principal investigator 1 Amgen Inc. $95,879.19 04/28/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246639727
Principal investigator 1 Eli Lilly and Company $3,053.18 03/25/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187880817
Principal investigator 1 Eli Lilly and Company $1,755.38 03/10/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187876127
Principal investigator 1 GlaxoSmithKline, LLC. $3,958.20 03/07/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192156698
Principal investigator 1 GlaxoSmithKline, LLC. $5,415.30 02/05/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192185481
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,356.00 01/30/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-1) No dispute reported 06/30/2026 1190303257
Principal investigator 1 Eli Lilly and Company $15,309.00 01/28/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187877075
Principal investigator 1 Eli Lilly and Company $1,410.65 01/27/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187874783
Principal investigator 1 Eli Lilly and Company $103,757.00 01/21/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187875481
Principal investigator 1 Eli Lilly and Company $50,259.00 01/21/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187877073
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,604.66 01/15/2025 Non-covered Recipient Entity
MEDVIN CLINICAL RESEARCH
A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-1) No dispute reported 06/30/2026 1190311199
Principal investigator 1 Amgen Inc. $1,752,831.52 01/14/2025 Non-covered Recipient Entity
MEDVIN CLINICAL RESEARCH
A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants No dispute reported 06/30/2026 1246644367
Principal investigator 1 GlaxoSmithKline, LLC. $7,595.10 01/08/2025 Non-covered Recipient Entity
BIOVIN ENTERPRISES LLC
A PHASE 4, MULTICENTER, PROSPECTIVE, OPEN-LABEL STUDY DESCRIBING THE E No dispute reported 06/30/2026 1192156708